The Role Of Respiratory Therapists And Nursing In Reducing And Preventing Of Ventilator-Associated Pneumonia

Background: Ventilator-associated pneumonia (VAP) comprises ~50% of nosocomial pneumonias and remains the most frequent infection among mechanically ventilated patients, driving mortality, prolonged ICU/hospital length of stay, antimicrobial exposure, and costs. Diagnostic ambiguity, shifting CDC definitions to ventilator-associated events (VAEs), and the SARS-CoV-2 era have complicated surveillance and benchmarking. Aim: To synthesize practical, evidence-based strategies—especially those enacted by respiratory therapists (RTs) and nursing—to reduce VAP incidence and improve patient-centered outcomes. Methods: Narrative integration of randomized trials, meta-analyses, and prospective cohorts cited in the source text, emphasizing core bundle elements (head-of-bed elevation, daily sedation interruption, spontaneous breathing trials), early mobilization, oral care/decontamination options, circuit stewardship, subglottic drainage, and implementation science. Results: Highest-yield measures shorten ventilator exposure and curb aspiration: semirecumbency (30°–45°), light/goal-directed sedation with daily awakening and synchronized SBTs, and early mobilization improve ventilator-free days and functional outcomes. Oral chlorhexidine reduces VAP chiefly in short-stay cardiac cohorts; signals of harm in general ICUs warrant caution. Subglottic drainage lowers early VAP, particularly within comprehensive bundles. Probiotics lack benefit. Compliance, education, and feedback loops determine real-world effectiveness. Conclusion: RT- and nursing-led, implementation-ready bundles that minimize ventilation days and aspiration—augmented by targeted technologies and antimicrobial stewardship—can meaningfully attenuate VAP while preserving resources.